Work

Imatinib Mesylate (IM) Versus IM + Low Dose of Pegylated Interferon Alfa 2a (Peg-IFN 2a) In Newly-Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML).

Year: 2010

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v116.21.4497.4497

Authors: Luis Antonio Meillon, Salvador Campos-Cabrera, Nancy Delgado-Lopez, Angel A. Fernandez-Martinez, Jesus Medrano-Contreras, Guillermo Gutierrez, Juan F. Perez-Rocha, Eduardo Terreros-Muñoz, Sue C. Gomez-Cortes, Susana Guerrero-Rivera, Kevin A. Nacho-Vargas

Institutions: Mexican Social Security Institute, Centro Medico Nacional Siglo XXI

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2563620482

FWCI:

Cites:

Cited by:

Related to: 10